The Biospecimen Core Resource within The Research Institute at Nationwide Children’s Hospital in Columbus, Ohio, has received a new $4.5 million federal contract to accept, process, ensure quality, and distribute tumor derivatives for a number of national cancer research projects. The Biospecimen Core Resource is part of a national processing and analysis pipeline supporting large-scale cancer genomic projects.
The new contract will fund the Biospecimen Core Resource to review and process all incoming tissue specimens to ensure they meet rigorous standards for downstream genomic characterization. Currently, the Biospecimen Core Resource processes specimens for such ventures as the Cancer Driver Discovery Project, Clinical Trials Sequencing Project, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, and Exceptional Responders Initiative, among others. The common goals of these studies are to unearth clues to the subclasses of different cancers and improve the medical community’s ability to diagnose, treat, and prevent the diseases.
This new contract is yet another in the long history supporting cancer tissue banking, processing, and testing at Nationwide Children’s Hospital. This new Biospecimen Core Resource funding is from the National Cancer Institute, the National Institutes of Health, and the Department of Health and Human Services. ■